Development and Validation of a Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Sofosbuvir, Velpatasvir, and Voxilaprevir in Tablet Formulation

By Deepthi R & Gowri Sankar D

Abstract- Objective: The present study aimed to develop a stability-indicating reverse-phase high performance-liquid chromatography (RP-HPLC) method for the estimation of Sofosbuvir, Velpatasvir, and Voxilaprevir in tablet dosage form and validated in accordance with ICH guidelines.

Methods: The optimized conditions for the developed RP-HPLC method are Agilent C18 (250 mm×4.6mm, 5µ) column maintained at 30°C with a mobile phase consisting of Buffer(0.1%OPA) and Acetonitrile taken in the ratio 55:45%v/v on isocratic mode at flow rate 1.0ml/min. The sample was detected at 220 nm.

Results: The retention time of Sofosbuvir, Velpatasvir, and Voxilaprevir was found to be 2.17, 2.731 and 3.55 min respectively. The developed method was validated for accuracy, precision, specificity, ruggedness, robustness and solution stability.

Keywords: stability-indicating, method development, validation, RP-HPLC, sofosbuvir.

GJMR-B Classification: NLMC Code: QV 55
Development and Validation of a Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Sofosbuvir, Velpatasvir, and Voxilaprevir in Tablet Formulation

Deepthi R & Gowri Sankar D

Abstract- Objective: The present study aimed to develop a stability-indicating reverse-phase high performance-liquid chromatography (RP-HPLC) method for the estimation of Sofosbuvir, Velpatasvir, and Voxilaprevir in tablet dosage form and validated in accordance with ICH guidelines.

Methods: The optimized conditions for the developed RP-HPLC method are Agilent C18 (250 mm×4.6mm, 5µ) column maintained at 30ºC with a mobile phase consisting of Buffer(0.1%OPA) and Acetonitrile taken in the ratio 55:45%v/v on isocratic mode at flow rate 1.0ml/min. The sample was detected at 220 nm.

Results: The retention time of Sofosbuvir, Velpatasvir, and Voxilaprevir was found to be 2.17, 2.731 and 3.55 min respectively. The developed method was validated for accuracy, precision, specificity, ruggedness, robustness and solution stability. The method obeyed Beer’s law in the concentration range of 10µg/ml-60µg/ml for Sofosbuvir, 2.5µg/ml-15µg/ml for Velpatasvir and 2.5µg/ml -15µg/ml for Voxilaprevir with a correlation coefficient of 0.99 9 for Sofosbuvir, Velpatasvir, and Voxilaprevir respectively.

Forced degradation studies were conducted by exposing the drug solution to various stress conditions such as acidic, basic, peroxide, neutral, photolytic and thermal conditions. The net degradation was found to be within the limits, indicating that the drug is stable in stressed conditions.

Conclusion: The developed method for the estimation of Sofosbuvir, Velpatasvir, and Voxilaprevir can be utilized for the routine analysis of the pharmaceutical dosage form.

Keywords: stability- indicating, method development, validation, RP-HPLC, sofosbuvir.

I. Introduction

Hepatitis C [1] is a liver infection which is caused by the Hepatitis C virus. The hepatitis C virus is a blood-borne virus and the most common modes of infection are through exposure to small quantities of infected blood. Globally, around 70 million people were suffering from Hepatitis C infection. Antiviral medicines like sofosbuvir, velpatasvir, and voxilaprevir, etc; can cure more than 95% of persons having Hepatitis C infection and reduce the causes of death.

Sofosbuvir [2] (Fig 1) is a nucleotide prodrug and a hepatitis C virus (HCV) NS5B polymerase inhibitor with potential HCV inhibiting activity. Used as an antiviral drug in the treatment of Hepatitis C virus. It is chemically (S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4dioxo3,4 dihydropyrimidin1(2H)yl)4fluoro3hydroxy4methyltetrahyd rofurany2yl)methoxy)(phenoxy)phenylamino) propanoate.

Velpatasvir [3] (Fig 2) is a NS5A inhibitor which is used together with sofosbuvir to treat chronic Hepatitis C infection. Used as an antiviral drug in the treatment of Hepatitis C virus. Chemically it is methyl \{(2S)-1-\{((2S,5S)-2-(9-\{2-\{(2S,4S)-1-\{(2R)-2-\{(methoxy carbonyl) amino\}-2-phenylacetyl\}-4-\{(methoxy methyl) pyrrolidin-2-yl\}-1H-imidazol-4-yl\}-1,11-dihydro[2] benzo-pyranol[4',3':6,7]naptho[1,2-d][imidazol-2-yl]-5-methyl-pyrrolidin-1-yl\}-3-methyl-1-oxobutan-2-yl\} carbamate.

Figure 1: Structure of Sofosbuvir

Figure 2: Structure of Velpatasvir
Voxilaprevir [4] (Fig 3) is a protease inhibitor and acts as a transporter of polypeptide. Used as an antiviral drug in the treatment of Hepatitis C virus. chemically it is (1R,18R,20R,24S,27S,28S)N\((1R,2R)\)2(Difluoromethyl)1\((1\text{methylcyclopropyl})\text{sulfonyl}\)carbomoyl\)cyclopropyl\)-28-ethyl-13,13-difluoro-7-methoxy-24-(2-methyl-2-propanyl)-22,25-dioxo-2,21dioxa4,11,23,26-tetra azapentaenacyclo nonacosa-3(12),4,6,8,10-pentaene-27-carboxamide.

**Figure 3: Structure of Voxilaprevir**

As per the literature survey [5-11], it is learned that very few HPLC methods have been reported for the determination of Sofosbuvir, Velpatavir, and Voxilaprevir individually and in combination by HPLC but there is no method for stability-indicating and simultaneous estimation of all the three drugs.

Therefore, there is a need to develop a rapid and reliable Stability-indicating HPLC method for the simultaneous determination of Sofosbuvir, Velpatavir, and Voxilaprevir in bulk and pharmaceutical dosage form.

## II. Materials and Methods

### a) Reagents and chemicals

Sofosbuvir, Velpatavir and Voxilaprevir working standards were procured from spectrum pharma research solutions, Hyderabad, as a gift sample. The VOSEVI tablets were supplied by the Medindia Pharma network. All the chemicals used were of AR grade purchased from Merck, Mumbai. All the solvents used were of HPLC grade purchased from Sigma-Aldrich, Mumbai.

### b) Chromatographic conditions and Instruments

WATERS HPLC 2695 SYSTEM equipped with quaternary pumps, Photo Diode Array detector, and an auto sampler integrated with Empower 2 software and Agilent C18 (250mm × 4.6mm, 5\(\mu\)) column was used for the determination of Sofosbuvir, Velpatavir, and Voxilaprevir. The optimized conditions included 0.1% Orthophosphoric acid (OPA) and acetonitrile (55:45%v/v) as mobile phase run on an isocratic mode at flow rate 1.0ml/min. The column was maintained at 300C and detection was done at 220nm. Other equipment used in the method was Ultrasonic bath sonicator (BVK Enterprises) and weighing balance (Denver).

c) **Preparation of Diluent**

A mixture of water and acetonitrile in the ratio of 50:50%v/v was used as diluents.

d) **Preparation of Mobile phase**

A mixture of 0.1% orthophosphoric acid and Acetonitrile in the ratio (55:45%v/v) was used as the mobile phase.

e) **Preparation of Standard and Sample solutions**

20mg, 5mg & 5mg of Sofosbuvir, Velpatavir and Voxilaprevir working Standards were transferred to 50ml of volumetric flasks separately, 3/4th of diluents (as mentioned) was added to all the three flasks and subjected for sonication for 10 minutes. The final volume was made up with diluents to obtain a final concentration of 400µg/ml of Sofosbuvir, 100µg/ml of Velpatavir, & 100µg/ml of Voxilaprevir respectively.

From the above stock solution, 1 ml was pipetted out into a 10ml volumetric flask and then the final volume was made with the same diluent. (40µg/ml of Sofosbuvir, 10µg/ml of Velpatavir and 10µg/ml of Voxilaprevir respectively)

10 Tablets (Vosevi) were weighed accurately and the average weight was calculated. An amount equivalent of 1 tablet was collected into a 50ml volumetric flask; 15ml of diluents was mixed and sonicated for around 30 minutes. It was then subjected to making the volume with diluents.

Filtered the solution and diluted 1ml of the above solution to 10ml with diluents. (40µg/ml of Sofosbuvir & 10µg/ml of Velpatavir & 10µg/ml of Voxilaprevir).

f) **Method Validation**

The developed method was validated in compliance with International Conference on Harmonization (ICH) guidelines [12, 13].

g) **Specificity**

The specificity of the method was determined by comparing the drug solution with the placebo solution and observed for the interference of placebo peak with drug peak.

h) **Accuracy**

The accuracy of the present method was determined by %recovery. The drug solution along with the sample was prepared in three concentration levels 50%, 100%, and 150%. Then the % recovery was calculated.

i) **Precision**

The precision of the method was estimated by injecting the six solutions of the standard into the HPLC system and the % relative standard deviation (%RSD) was calculated.
j) Linearity

The linearity of the method was developed by preparing series of dilutions ranging from 12.5µg/ml - 75µg/ml for Bictegravir, 50µg/ml-300µg/ml for Emtricitabine and 6.25µg/ml-37.5µg/ml for Tenofovir alafenamide respectively and injecting them into HPLC system.

k) Ruggedness

Ruggedness was determined by injecting the six solutions of the standard into HPLC for different days. The % RSD was calculated.

l) Robustness

Robustness of the method was determined by varying the optimized analytical conditions such as mobile phase composition by ±5%, flow rate by ±0.1ml/min and column temperature by ±5°C.

m) LOD and LOQ

Calculation of limit of detection as well as Limit of quantification had been done by using standard Equations. LOD = 3.3×σ/S, LOQ =10×σ/S. Here σ denotes for the standard deviation of intercepts of regression lines, S denotes for slope.

n) Solution stability

Solution stability was estimated by analyzing the standard drug solution after storage for 24hrs under laboratory conditions.

o) Forced degradation studies

Forced degradation studies[14] were carried out for drug by exposing the drug solution to the various stress conditions such as acidic (2N Hydrochloric acid for 30min at 60ºC), basic (2N Sodium hydroxide for 30min at 60ºC), Oxidation (refluxing the drug solution with 20%H2O2), neutral (refluxing the drug in water for 6h at 60ºC), photolytic (exposing the drug solution to UV light by keeping the solution in UV chamber for 7 days or 200-watt hrs/m2 in photostability chamber), thermal (drug solution was placed in oven at 105ºC for 6hrs) conditions.

III. RESULTS

![Optimized chromatogram of Sofosbuvir, Velpatasvir, and Voxilaprevir](image)

**Table 1: System suitability and validation parameter results**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Result</th>
<th>Sofosbuvir</th>
<th>Velpatasvir</th>
<th>Voxilaprevir</th>
</tr>
</thead>
<tbody>
<tr>
<td>USP Plate count</td>
<td>4088</td>
<td>10175</td>
<td>126558</td>
<td></td>
</tr>
<tr>
<td>USP Tailing factor</td>
<td>1.0</td>
<td>1.2</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>USP Resolution</td>
<td>4.5</td>
<td>-</td>
<td>7.2</td>
<td></td>
</tr>
<tr>
<td>Precision (%RSD)</td>
<td>0.9</td>
<td>0.8</td>
<td>0.4</td>
<td></td>
</tr>
<tr>
<td>Accuracy</td>
<td>98.50-101.50</td>
<td>98.50-101.50</td>
<td>98.50-101.50</td>
<td></td>
</tr>
<tr>
<td>Specificity</td>
<td>Specific, No interference</td>
<td>Specific, No interference</td>
<td>Specific, No interference</td>
<td></td>
</tr>
<tr>
<td>Linearity range (µg/ml)</td>
<td>10-60</td>
<td>2.5-15</td>
<td>2.5-15</td>
<td></td>
</tr>
<tr>
<td>Correlation coefficient, r²</td>
<td>0.999</td>
<td>0.999</td>
<td>0.999</td>
<td></td>
</tr>
<tr>
<td>LOD (µg/ml)</td>
<td>0.11</td>
<td>0.10</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>LOQ (µg/ml)</td>
<td>0.34</td>
<td>0.29</td>
<td>0.17</td>
<td></td>
</tr>
<tr>
<td>Ruggedness (%RSD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day1</td>
<td>0.9</td>
<td>0.8</td>
<td>0.4</td>
<td></td>
</tr>
<tr>
<td>Day2</td>
<td>0.9</td>
<td>1.9</td>
<td>0.6</td>
<td></td>
</tr>
<tr>
<td>Robustness (%RSD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flow rate –</td>
<td>1.2</td>
<td>1.1</td>
<td>1.0</td>
<td></td>
</tr>
</tbody>
</table>
Flow rate + 3.4 3.7 3.7
Column temperature – 2.8 2.7 2.9
Column temperature + 2.2 2.4 2.2
Mobile phase – 3.8 3.4 3.2
Mobile phase + 2.4 2.7 2.4
Solution stability (%RSD)
(0 hrs) 1.0 0.6 1.0
(24 hrs) 0.9 1.0 0.6

Table 2: Forced degradation studies result

<table>
<thead>
<tr>
<th>Stress condition</th>
<th>Sofosbuvir</th>
<th>Velpatasvir</th>
<th>Voxilaprevir</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%Assay</td>
<td>%D</td>
<td>%Assay</td>
</tr>
<tr>
<td>Acid</td>
<td>94.23</td>
<td>5.77</td>
<td>94.04</td>
</tr>
<tr>
<td>Base</td>
<td>95.35</td>
<td>4.65</td>
<td>95.10</td>
</tr>
<tr>
<td>Neutral</td>
<td>99.37</td>
<td>0.63</td>
<td>99.51</td>
</tr>
<tr>
<td>Peroxide</td>
<td>95.95</td>
<td>4.05</td>
<td>95.58</td>
</tr>
<tr>
<td>Photolytic</td>
<td>97.73</td>
<td>2.27</td>
<td>97.58</td>
</tr>
<tr>
<td>Thermal</td>
<td>98.22</td>
<td>1.75</td>
<td>96.43</td>
</tr>
</tbody>
</table>

%D- Percentage Degradation

Figure 5: Blank chromatogram

Figure 6: Standard chromatogram
**Figure 7:** Sample chromatogram

**Figure 8:** Placebo chromatogram

**Figure 9:** Linearity plot of Sofosbuvir

\[ y = 22616x + 6259. \quad R^2 = 0.999 \]

**Figure 10:** Linearity plot of Velpatasvir

\[ y = 22286x + 1102. \quad R^2 = 0.999 \]
Development and Validation of a Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Sofosbuvir, Velpatasvir, and Voxilaprevir in Tablet Formulation

**Figure 11:** Linearity plot of Voxilaprevir

![Linearity plot of Voxilaprevir](image1.png)

\[ y = 25052x + 1805. \]

\[ R^2 = 0.999 \]

**Figure 12:** HPLC Chromatogram of Acid Degraded sample

![HPLC Chromatogram of Acid Degraded sample](image2.png)

**Figure 13:** HPLC Chromatogram of Alkali Degraded sample

![HPLC Chromatogram of Alkali Degraded sample](image3.png)

**Figure 14:** HPLC Chromatogram of Peroxide Degraded sample

![HPLC Chromatogram of Peroxide Degraded sample](image4.png)

© 2020 Global Journals
IV. DISCUSSION

For the development of a new method for the simultaneous estimation of Sofosbuvir, Velpatasvir, and Voxilaprevir in bulk and pharmaceutical dosage form initially many mobile phases and many columns were tried to elute the drug peak with less tailing factor, more plate count and more resolution.

Waters HPLC Agilent C18 (250mm × 4.6mm, 5µ) column and Buffer: Acetonitrile (55:45%v/v) as mobile phase were selected based on peak parameters. The detection wavelength was found to be 220nm.

Prepared standard solution, sample solution, and blank solution were injected into the HPLC system and system suitability parameters were noted as summarized in Table 1 along with chromatograms as shown in fig. 4, 5, 6 and 7 respectively.

The developed method was found to obey Beer’s law in the concentration range of 10-60 µg/ml for Sofosbuvir, 2.5-15 µg/ml for velpatasvir and 2.5-15 µg/ml for Voxilaprevir with a correlation coefficient of 0.999 each respectively. A linear graph was plotted between concentration and peak area as shown in fig.
9.10 and 11 respectively and results are summarized in Table 1.

The method was found to be accurate as the %
recovery was 98.50%-101.50% for all the three drugs
and was within the limits. The %RSD was found to be
less than 1 for all the three drugs indicates that the
method was precise. The method was found to be
specific, as there is no interference of retention time of
placebo peak with that of drug peak. The placebo
chromatogram was shown as fig. 8.

Forced degradation studies results indicate that
the drug was found to be stable in various stress
conditions as net degradation was found to be within
the limits. The chromatograms were shown in fig. 12-17
and results were summarized in Table 2.

V. Conclusion

A specific, precise, stability-indicating method
was developed for the determination of Sofosbuvir,
Velpatasvir, and Voxilaprevir in pure and tablet dosage
form using RP-HPLC. The method was validated by
using various validation parameters and the method
was found to be linear, precise, accurate, specific and
robust. From the degradation, studies conducted it is
concluded that Sofosbuvir, Velpatasvir, and Voxilaprevir
were stable at high concentrations of Acid, Base,
Peroxide, Thermal, UV and Water stress study
conditions. The run time was 5min which enables rapid
quantitation of many samples in routine and quality
control analysis of tablet formulations.

Acknowledgment

The authors are thankful to the pharma research
solutions, Hyderabad for providing the Sofosbuvir,
Velpatasvir, and Voxilaprevir as the gift samples and
also for providing required facilities to carry out this
research work.

Conflict of Interests

The authors claim that they have no conflict of
interest. It has not meant to publish elsewhere.
Moreover, it has not meant simultaneously presented for
publication elsewhere.

References Références Referencias

1. https://www.who.int/news-room/fact-sheets/detail/
hepatitisC
5. Sandhya Rani J and Devanna N. Development and
validation of RP-HPLC method for the simultaneous
estimation of Sofosbuvir, velpatasvir, and
voxilaprevir in bulk and tablet dosage forms.
development and validation for simultaneous
estimation of sofosbuvir and velpatasvir in a
pharmaceutical dosage form. International Journal
of Engineering Technology Science and Research,
2017; 4,(11):145-152.
7. Geetha Susmitha A and Rajitha G. Development
and validation of stability indicating UPLC method
for simultaneous estimation of sofosbuvir and
velpatasvir in a tablet dosage form. International
journal of pharmaceutical sciences and research,
8. Lakshmana Rao A and Pallavi A. Method
Development and Validation of Stability Indicating
RP-HPLC Method for Simultaneous Estimation of
Sofosbuvir and Velpatasvir in Tablet Dosage Form.
Pharmaceutical Sciences & Analytical Research
9. Balaswami, B; Ramana, P Venkata; Rao, B Subba;
Sanjeeva, P. A New Simple Stability-Indicating RP-
HPLC- PDA Method for Simultaneous Estimation of
Triplicate Mixture of Sofosbuvir, Velpatasvir, and
Voxilaprevir in Tablet Dosage Form. Research
Journal of Pharmacy and Technology, 2018;
11(9):4147-4156.
10. Memthoibi Devi L, Dr.Rama Mohan Reddy T,
Dr.Abbulu K. Simultaneous determination and
validation of third generation antiviral drugs by RP-
HPLC method. International journal of pharmacy
11. Lalitha KV, Raveendra Reddy J, and N Devanna N.
Stability indicating RP-HPLC method development
and validation for estimation of Sofosbuvir in a
pharmaceutical dosage form. The Pharma
12. ICH: Q2 [R1], Validation of analytical procedures:
text and methodology; 2005.
13. ICH: Q2B. Harmonized Tripartite Guideline,
Validation of Analytical Procedure: Methodology,
IFPMA, in Proceedings of the International
Conference on Harmonization, Geneva; 1996.
14. Ngwa G. Forced degradation studies as an integral
delopment and Validation of a Stability-Indicating RP-HPLC Method for the Simultaneous
part of HPLC stability indicating method
determination of Sofosbuvir, Velpatasvir, and Voxilaprevir in Tablet Formulation
dev and Validation of Stability-Indicating RP-

© 2020 Global Journals